1300018I emory university; vteu; to: 14-0107.B1C1D1.0023 protocol development(BASE) and research assays(option 5) relative to protocol 14-0107, a a phase I trial to evaluate the safety,…

Ended Awarded Last action

Contract number
HHSN27200007
Awardee
Awarding agency
Obligated
$869,835

Award facts

Opportunity
Contract value 100% obligated
$869,835.27 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 6 offers Multiple Award, Fair Opportunity
Pricing
Cost No Fee
Place of performance
Atlanta, GA 30322, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Close Out P00007 -$96
Supplemental Agreement for work within scope P00006 $0
Supplemental Agreement for work within scope P00005 $0
Other Administrative Action 4 $0
Funding Only Action 3 · Vaccine and treatment evaluation units (VTEU) protocol development, implementation and assays task area B-D task order 14-0107.B1C1D1.0023 $186,478
Other Administrative Action 2 · This modification is to extend the period of performance of task area D-option 5, line item 2, from july 1, 2015 through december 31, 2016 to july 1, 2015… $0
Other Administrative Action 1 · This modification is to extend the period of performance of the base from july 1, 2015 through february 15, 2016 to july 1, 2015 through june 15, 2016. $0
Original award $683,453

About this award

Written by GovTribe AI ·

This federal contract award was granted by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Emory University, a private university and nonprofit organization. The contract, valued at $869,835.27, is a delivery order under the Vaccine and Treatment Evaluation Units (VTEU) indefinite delivery contract vehicle. The contract supports protocol development and research assays related to a Phase I clinical trial evaluating the safety, reactogenicity, and immunogenicity of the MVA-BN Yellow Fever vaccine, with and without an ISA 720 adjuvant, in healthy volunteers aged 18-45. This work is being conducted as part of Emory's role as a VTEU, which are a network of academic and research institutions that collaborate with NIAID on vaccine and treatment evaluation. The contract does not have a set-aside designation.

Description

As the agency reported it.

1300018I emory university; vteu; to: 14-0107.B1C1D1.0023 protocol development(BASE) and research assays(option 5) relative to protocol 14-0107, a a phase I trial to evaluate the safety, reactogenicity, and immunogenicity ofmva-BN yellow fever vaccine with and without ISA 720 adjuvant in 18-45 year old healthy volunteers.

Quick answers

Who was awarded contract HHSN27200007?

HHSN27200007 was awarded to Emory University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 23, 2015.

How much is contract HHSN27200007 worth?

The government has obligated $869,835 on HHSN27200007.

Is contract HHSN27200007 an order under another contract?

Yes. HHSN27200007 is a delivery order under HHSN272201300018I, an indefinite delivery contract, on Vaccine and Treatment Evaluation Units (VTEU).

Was contract HHSN27200007 competed?

The extent of competition for HHSN27200007 was full and open competition. The government received 6 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login